Surveillance in 0–6 months | Surveillance in 7–24 months | Unadjusted HR (95% CI) | Adjusted HR (95% CI)* | Adjusted HR (95% CI) with HCC treatment† |
No | No | Ref. | Ref. | Ref. |
No | Yes | 0.84 (0.69 to 1.01) | 0.93 (0.77 to 1.13) | 0.94 (0.78 to 1.14) |
Yes | No | 0.80 (0.68 to 0.94) | 0.93 (0.79 to 1.09) | 0.97 (0.83 to 1.15) |
Yes | Yes | 0.71 (0.62 to 0.82) | 0.84 (0.72 to 0.98) | 0.93 (0.80 to 1.09) |
↵* Adjusted for received a screening test in the 3–6 years before HCC, year of HCC diagnosis, age, race, MELD score, psychosis, ascites, varices and encephalopathy.
↵† Adjusted for screening test received in the 3–6 years before HCC, year of HCC diagnosis, age, race, MELD score, psychosis, ascites, varices, encephalopathy, transplant, resection, TACE/TAE and RFA.
Results were obtained from Cox proportional hazards regression analyses.
MELD, Model for End Stage Liver Disease; RFA, radiofrequency ablation; TACE/TAE, transarterial (chemo)embolisation.